India, April 9 -- Shares of Phio Pharmaceuticals Corp. (PHIO) more than doubled on Wednesday morning after the company announced the Safety Monitoring Committee has recommended to proceed with dose escalation in its clinical trial of PH-762.
PHIO is currently trading at $2.1800, up $1.1700 or 115.8416%, on a huge volume of 100 million shares, above average volume of 6.2 million, on the Nasdaq. The stock opened its trading at $2.1350 after closing Tuesday at $1.0100. The stock has traded between $0.9660 and $9.7900 in the past 52-week period.
PH-762, the company's lead drug candidate works by silencing the PD-1 gene implicated in various forms of skin cancer.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0');...